Andrew J. Mills - 16 Dec 2025 Form 4 Insider Report for Medline Inc. (MDLN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
22 Dec 2025, 16:30:06 UTC
Next SEC filing
17 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nicole Fritz, Attorney-in-Fact

Key filing fact

Andrew J. Mills filed Form 4 for Medline Inc. (MDLN) on 22 Dec 2025.

Key facts

  • This page summarizes Andrew J. Mills's Form 4 filing for Medline Inc. (MDLN).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 22 Dec 2025, 16:30.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: +$74,999,974.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001460212 Primary reporting owner

Mills Andrew J.

Relationship
Director
Address
C/O MEDLINE INC., 3 LAKES DRIVE, NORTHFIELD
Signature
/s/ Nicole Fritz, Attorney-in-Fact
Signature date
22 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDLN transaction

Class B Common Stock

Award

Transaction value
Shares
+30,655
Change %
Price
Shares after
30,655
Date
16 Dec 2025
Ownership
See Footnote
Footnotes
F1, F2
MDLN transaction

Class A Common Stock

Purchase

Transaction value
$74,999,974
Shares
+2,586,206
Change %
Price
$29.00
Shares after
2,586,206
Date
18 Dec 2025
Ownership
See Footnote
Footnotes
F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDLN transaction Derivative

Common Units of Medline Holdings, LP

Award

Transaction value
Shares
+30,655
Change %
Price
Shares after
30,655
Date
16 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
30,655
Exercise price
Footnotes
F1, F2, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.

Footnote F2

These securities are held by a trust for the benefit of the Reporting Person and members of his immediate family, and of which the Reporting Person has the power to replace the trustee. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Footnote F3

Reflects shares of Class A Common Stock of the Issuer acquired in the initial public offering of Class A Common Stock of the Issuer at the initial public offering price and on the same terms as the other purchasers in the initial public offering.

Footnote F4

These securities are held for the benefit of the Reporting Person and members of his immediate family by a limited liability company. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Footnote F5

Pursuant to the terms of an exchange agreement, dated as of December 16, 2025, holders have the right to exchange their common units of Medline Holdings, LP for shares of the Issuer's Class A common stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .